Why the study?
Does the addition of multiple drug chemotherapy to local therapy improve disease-free survival in patients with Ewing's sarcoma?
Does the addition of multiple drug chemotherapy to local therapy improve disease-free survival in patients with Ewing's sarcoma?
The addition of multi-agent chemotherapy to local therapy substantially prolonged disease-free survival in patients with localized Ewing's sarcoma.
Answers are grounded in this paper and cite their sources.
Does not yet support changing practice for localized Ewing's sarcoma; hypothesis-generating for multi-agent chemotherapy benefit.
The series comprises 57 consecutive patients with Ewing's sarcoma admitted to the National Cancer Institute of Milan from 1965 to 1976. In 75% the diseas was confined to one bone, while in 25% multiple bone and/or visceral lesions were present. Patients with clinically localized tumor treated before 1971 with local therapy, showed a median disease-free survival of 5 months. After 1971, radiotherapy and/or surgery to local tumor was combined with multiple drug chemotherapy (ADM, VCR, CTX) and the projected median disease-free survival increased to 24+ months. In previously untreated patients with advanced tumor adriamycin, used as single drug, achieved an overall response rate of 73%. This is comparable to that achieved by a new combination including ADM, VCR, CTX, CCNU (75%). This multiple drug regimen is, however, expected to prolong the duration of response.
No takes yet. Share an insight, caveat, or question.
Gasparini et al. (1977) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: